Skip to content
Screener

Xencor XNCR Total Liabilities & Equity

Total Liabilities & Equity at other companies

Amgen logo
AmgenAMGN
$95.64B+8.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Janux Therapeutics logo
Janux TherapeuticsJANX
$1.01B-2.4%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$1.31B-6.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$329.68M-21.9%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$95.82M+382%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemJune 30,2026December 31,2025
Common stock, $0.01 par value: Authorized 200,000 sharesIssued and outstanding 74,329 and 71,872 shares at June 30, 2026 and December 31, 2025, respectively.744718
Additional paid-in capital1,449,9601,429,252
Accumulated other comprehensive (loss) income(872)1,576
Accumulated deficit(946,604)(795,959)
Total stockholders’ equity attributable to Xencor, Inc.503,228635,587
Noncontrolling interest
Total noncontrolling interest and stockholders’ equity503,228635,587
Total liabilities and stockholders’ equity$724,960$875,495

Item 1. Financial Statements

FAQ

What is Xencor's total liabilities & equity?
Xencor (XNCR) reported total liabilities & equity of $724.96M in Q2 2026.
How has Xencor's total liabilities & equity changed year-over-year?
Xencor's total liabilities & equity decreased by 17.6% year-over-year, from $879.42M to $724.96M.
What is the long-term trend for Xencor's total liabilities & equity?
Over 5 years (2020 to 2025), Xencor's total liabilities & equity has grown at a 4.5% compound annual growth rate (CAGR), from $703.24M to $875.5M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Xencor's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude